FOLFOXIRI promising in metastatic colorectal cancer

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1587, 2007-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art

Clinical Cancer Drugs, Vol. 1, Iss. 1, 2014-01 ,pp. : 78-83

Bentham Science Publishers

Access to resources Recommend Favorite

Capecitabine, oxaliplatin plus erlotinib is promising for the treatment of metastatic colorectal cancer

Inpharma, Vol. 1, Iss. 1538, 2006-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Chemotherapy for Metastatic Colorectal Cancer

By Rosales Joseph Leong Lucille A.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 3, Iss. 4, 2005-07 ,pp. : 525-529

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

FOLFIRI better value than FOLFOXIRI for metastatic CRC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 538, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Panitumumab: In the Treatment of Metastatic Colorectal Cancer

By Hoy Sheridan M. Wagstaff Antona J.

Drugs, Vol. 66, Iss. 15, 2006-01 ,pp. : 2005-2014

Adis International

Access to resources Recommend Favorite